Graham Garrison
Neurocritical Care · Cincinnati, OHNPI 1558628081
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $505 and has fallen 85.9% since, to $71 in 2025.
Across 55 payments — averaging $12.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$154
- Teva Pharmaceuticals USA, Inc.$129
- Novartis$86
- Biogen$67
- Ipsen Biopharmaceuticals, Inc$49
- UCB, Inc.$39
- plus $173 from 9 others
Across 1 payment — averaging $2556.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$3K
What the payments were for
- Food & beverage$696100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 9 | $154 |
| Teva Pharmaceuticals USA, Inc. | 23 | $129 |
| Novartis | 4 | $86 |
| Biogen | 4 | $67 |
| Ipsen Biopharmaceuticals, Inc | 1 | $49 |
| UCB, Inc. | 3 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| AstraZeneca | 2 | $33 |
| Medtronic | 1 | $20 |
| Sanofi | 1 | $17 |
| Merz North America, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$696 in reported general payments places this provider in the 55th percentile of 30 neurocritical care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 40 | $46,125 |
| Emgality SyringeGalcanezumab-Gnlm | 18 | $17,206 |
| Emgality PenGalcanezumab-Gnlm | 18 | $12,477 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $11,213 |
| AmantadineAmantadine Hcl | 27 | $3,088 |
| Gabapentin | 101 | $1,419 |
| Levetiracetam | 24 | $1,115 |
| Propranolol Hcl ErPropranolol Hcl | 26 | $916 |
| Primidone | 11 | $873 |
| Baclofen | 30 | $814 |
| Donepezil Hcl | 11 | $690 |
| Nortriptyline Hcl | 21 | $316 |
| Duloxetine Hcl | 11 | $256 |
| Galantamine ErGalantamine Hbr | 12 | $250 |
| Pregabalin | 12 | $163 |
Paid to pharmacies, not to this prescriber.
Other neurocritical care in Cincinnati
- John KachorisCincinnati$6K
- Matthew SmithCincinnati$2K
- Christopher ZammitCincinnati$693
- Ren-Shuoh KuoCincinnati$201
- Deep PatelCincinnati$190
- Kiran PoudelCincinnati$145
- David RobinsonCincinnati$126
- Barbara BasilCincinnati$106
- Lachelle VanceCincinnati$59
- Michel TorbeyColumbus$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.